乳腺癌患者血清ST2蛋白水平改变及其临床意义

Change and significance of serum soluble ST2 level in patients with ER-positive breast cancer

目的探讨乳腺癌患者血清人基质裂解素(ST2)的变化及其与乳腺癌发展和预后的关系。方法采用酶联免疫吸附(ELISA)法检测102例乳腺癌患者血清中ST2水平,分析血清ST2水平与患者临床病理特征的关系,评价ST2用于预测预后的价值。结果雌激素受体(ER)阳性乳腺癌患者血清ST2水平高于ER阴性组及对照组,而ER阴性组与对照组血清ST2无差别;血清ST2水平的高低与ER阳性乳腺癌患者病理分型、TNM分期、淋巴结转移和远处转移情况有关;高ST2组ER阳性乳腺癌患者预后比低ST2组ER阳性乳腺癌患者差。结论血清ST2可用于预测ER阳性乳腺癌患者的预后。

Objective To investigate the change of serum ST2 level in breast cancer patients and its relation with the development and prognosis of breast cancer. Methods Serum ST2 levels in 102 breast cancer patients were detected by the enzyme-linked immunosorbent assay（ELISA）;the relationship between ST2 level with the clinico- pathologic features was analyzed;the Kaplan-Meier method was used to conduct the survival analysis and evaluate the value of ST2 for predicting the prognosis. Results The serum ST2 level in the ER-positive breast cancer patients were higher than that in the ER-negative patients, while there was no difference between the ER negative patients with healthy controls;serum ST2 level was correlated with the pathological type,TNM stage,lymph node metastasis and distant metastasis;the prognosis of the patients with ER-positive breast cancer in the high serum ST2 level group was pobrer than that in the low serum ST2 level group. Conclusion The serum ST2 level can be used to predict the prognostic in the patients with ER-positive breast cancer.